115 related articles for article (PubMed ID: 11226519)
1. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells.
Deaglio S; Canella D; Baj G; Arnulfo A; Waxman S; Malavasi F
Leuk Res; 2001 Mar; 25(3):227-35. PubMed ID: 11226519
[TBL] [Abstract][Full Text] [Related]
2. Co-biomodulation with arsenic trioxide in multiple myeloma.
Gallagher RE
Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
[No Abstract] [Full Text] [Related]
3. Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells.
Cesano A; Visonneau S; Deaglio S; Malavasi F; Santoli D
J Immunol; 1998 Feb; 160(3):1106-15. PubMed ID: 9570523
[TBL] [Abstract][Full Text] [Related]
4. Trials of arsenic trioxide in multiple myeloma.
Hussein MA
Cancer Control; 2003; 10(5):370-4. PubMed ID: 14581891
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma.
Hussein MA
Med Oncol; 2001; 18(4):239-42. PubMed ID: 11918450
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol.
Semenov I; Akyuz C; Roginskaya V; Chauhan D; Corey SJ
Leuk Res; 2002 Mar; 26(3):271-80. PubMed ID: 11792416
[TBL] [Abstract][Full Text] [Related]
7. NAD degradation and regulation of CD38 expression by human monocytes/macrophages.
Pfister M; Ogilvie A; da Silva CP; Grahnert A; Guse AH; Hauschildt S
Eur J Biochem; 2001 Nov; 268(21):5601-8. PubMed ID: 11683883
[TBL] [Abstract][Full Text] [Related]
8. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
9. [Detection of myeloma cells in the peripheral blood using flow cytometry].
Adam Z; Klabusay M; Vorlícek J; Hájek R
Vnitr Lek; 1997 Sep; 43(9):592-8. PubMed ID: 9750468
[TBL] [Abstract][Full Text] [Related]
10. All-trans-retinoic acid up-regulates CD38 but not c-Kit antigens on human marrow CD34+ cells without recruitment into cell cycle.
Herault O; Domenech J; Degenne M; Bremond JL; Sensebe L; Bernard MC; Binet C; Colombat P
Br J Haematol; 1998 Nov; 103(2):343-50. PubMed ID: 9827903
[TBL] [Abstract][Full Text] [Related]
11. CD38/ADP-ribosyl cyclase: A new role in the regulation of osteoclastic bone resorption.
Sun L; Adebanjo OA; Moonga BS; Corisdeo S; Anandatheerthavarada HK; Biswas G; Arakawa T; Hakeda Y; Koval A; Sodam B; Bevis PJ; Moser AJ; Lai FA; Epstein S; Troen BR; Kumegawa M; Zaidi M
J Cell Biol; 1999 Sep; 146(5):1161-72. PubMed ID: 10477767
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide: an emerging therapy for multiple myeloma.
Munshi NC
Oncologist; 2001; 6 Suppl 2():17-21. PubMed ID: 11331436
[TBL] [Abstract][Full Text] [Related]
13. Human CD38 is an authentic NAD(P)+ glycohydrolase.
Berthelier V; Tixier JM; Muller-Steffner H; Schuber F; Deterre P
Biochem J; 1998 Mar; 330 ( Pt 3)(Pt 3):1383-90. PubMed ID: 9494110
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells.
Altomonte M; Gloghini A; Bertola G; Gasparollo A; Carbone A; Ferrone S; Maio M
Cancer Res; 1993 Jul; 53(14):3343-8. PubMed ID: 7686816
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide in multiple myeloma: rationale and future directions.
Anderson KC; Boise LH; Louie R; Waxman S
Cancer J; 2002; 8(1):12-25. PubMed ID: 11895198
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of ADP-ribosyl cyclase activity of the cell surface antigen CD38 by zinc ions resulting from inhibition of its NAD+ glycohydrolase activity.
Kukimoto I; Hoshino S; Kontani K; Inageda K; Nishina H; Takahashi K; Katada T
Eur J Biochem; 1996 Jul; 239(1):177-82. PubMed ID: 8706705
[TBL] [Abstract][Full Text] [Related]
17. Human CD38: a (r)evolutionary story of enzymes and receptors.
Deaglio S; Mehta K; Malavasi F
Leuk Res; 2001 Jan; 25(1):1-12. PubMed ID: 11137554
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
[TBL] [Abstract][Full Text] [Related]
20. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Jourdan M; Ferlin M; Legouffe E; Horvathova M; Liautard J; Rossi JF; Wijdenes J; Brochier J; Klein B
Br J Haematol; 1998 Mar; 100(4):637-46. PubMed ID: 9531328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
